Answers are grounded in this paper and cite their sources.
Phase I trial demonstrates manageable safety and efficacy of CAR T-cell therapy in patients with systemic lupus erythematosus, indicating potential for treatment.
Background/Aims Patients with severe, refractory SLE (srSLE) have few treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion of the B-cell lineage, including plasmablasts. Obecabtagene autoleucel (obe-cel) is an autologous CD19-directed CAR T with a fast off-rate binding domain designed to reduce immunotoxicity, approved in adult relapsed/refractory B-cell acute lymphoblastic leukaemia. We report initial safety and preliminary efficacy results from the single-arm, open-label, dose-finding, Phase I CARLYSLE study (NCT06333483). Methods Eligible patients (12-65 years old) had SLE per the 2019 EULAR/ACR criteria, a ≥ 8-point SLEDAI-2K score at screening with ≥1 major SLE-related organ involvement, and were refractory to multiple prior standard-of-care medications. Following lymphodepletion with fludarabine (3 × 25 mg/m2) and cyclophosphamide (1 × 1,000 mg/m2), obe-cel was administered as a single starting flat dose of 50 × 106 (±20%) CAR T-cells. Primary endpoints: incidence of dose limiting toxicities (DLTs) within 28 days of infusion; frequency of adverse events. Secondary endpoints included: SLEDAI-2K; PGA; pharmacokinetics (PK); autoantibody and biomarker levels over time. Results As of 17 March 2025, seven patients were enrolled and six infused with obe-cel, with up to 8 months of follow-up. At baseline, all infused patients had active srSLE (SLEDAI-2K range: 15-28), class III or IV lupus nephritis; four also had class V. Four patients had elevated serum creatinine and an estimated glomerular filtration rate of < 60 mL/min/1.73m2; six patients had elevated urinary protein-creatinine ratio. Patients were refractory to B-cell therapies and immunosuppressants (median: 5 prior medicines; range: 5-6). No DLTs or immune effector cell-associated neurotoxicity syndrome (ICANS) occurred. Three patients experienced Grade 1 cytokine release syndrome (CRS) with no Grade ≥2 CRS. Transient/manageable hypertension occurred in five patients and all patients had transient Grade ≥3 neutropenia. Infections were manageable; none were life-threatening. Four patients with ≥3 months follow-up showed ≥10-point SLEDAI-2K reduction and complete resolution of non-renal symptoms within 3 months. Steroids were tapered to ≤ 10mg/day post obe-cel infusion; no other SLE medications were administered. Three of six patients achieved complete renal response (CRR) at last follow-up, one at Month 1 (M1) and two at M3. Complement C3 normalized and anti-double-stranded DNA antibody decreased in all six patients by M1 compared with baseline levels. PK data indicated robust CAR T-cell expansion; peak expansion was reached at a median of 10 days. Three patients had ongoing CAR T-cell persistence at last follow-up. Conclusion Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no DLTs, ICANS or Grade ≥2 CRS. All patients showed SLEDAI-2K score reduction and clinical benefit, including three patients with CRR. Despite the short follow-up and small cohort, initial findings are promising; further research is warranted. Updated data will be presented at the conference. Disclosure M. Leandro: Consultancies; Roche Basel, UCB, GSK. Grants/research support; Roche Basel. Other; PI for Clinical Trials on B-cell targeting therapies: Roche Basel, Autolus Therapeutics, BMS, Artiva, Fate Therapeutics. R. Pepper: Honoraria; Stada Arzneimittel symposium. Other; Advisor/review panel member: Vifor, Roche, Autolus Therapeutics. B. Parker: Honoraria; Otsuka. Grants/research support; LUPUS UK. Other; Advisor/Review Panel Member for Autolus Therapeutics, Conference attendance - UCB. E. Tholouli: Consultancies; Autolus Therapeutics, Bristol Myers Squibb/Celgene, Janssen, Kite/Gilead, Vertex. Honoraria; Amgen, Astellas, Jazz Pharmaceuticals, Kite/Gilead Sciences, Sobi, Pfizer, Takeda, Vertex. Other; Manchester Royal Infirmary. D. Jayne: None. B. Uttenthal: Consultancies; Sartorius, Swarm Oncology, Analog Devices. Honoraria; Kite. Other; Sponsorship to attend conferences: Kyverna, Advisor/review panel member: Kite/Gilead and Kyverna. J. Cortés-Hernández: Honoraria; AstraZeneca, GSK, Novartis. Grants/research support; Novartis. Other; Advisor/review panel member for Novartis; Bristol Myers Squibb. P. Barba: Grants/research support; Allogene, Amgen, Bristol Myers Squibb, InCyte, Gilead Sciences, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar, Novartis, Pfizer, Pierre Fabre. J. Román Ivorra: None. Y. Hu: Shareholder/stock ownership; Autolus Therapeutics. Other; Employee - Autolus Therapeutics. W. Brugger: Shareholder/stock ownership; Autolus Therapeutics. Other; Employee - Autolus Therapeutics. S. Basilico: Shareholder/stock ownership; Autolus Therapeutics. Other; Employee - Autolus Therapeutics. D. Germano: Shareholder/stock ownership; Autolus Therapeutics. Other; Employee - Autolus Therapeutics. C. Roddie: Consultancies; Autolus Therapeutics, Bristol Myers Squibb, Gilead, J+J, Miltenyi Biomedicine. Honoraria; Autolus Therapeutics, Bristol Myers Squibb, Gilead, Autolus Therapeutics (Speaking or Teaching), Bristol Myers Squibb (Speaking or Teaching), Gilead (Speaking or Teaching).
No takes yet. Share an insight, caveat, or question.
Leandro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: